Cas:1392273-41-4 Methyl 3-amino-2,6-difluorobenzoate hydrochloride manufacturer & supplier

Chemical Name:Methyl 3-amino-2,6-difluorobenzoate hydrochloride

CAS.NO:1392273-41-4

Synonyms:methyl 3-amino-2,6-difluorobenzoate,hydrochloride

Molecular Formula:C₈H₈ClF₂NO₂

Molecular Weight:223.60400

HS Code:2922499990

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.32000

Exact Mass:223.02100

LogP:2.71680

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like methyl 3-amino-2,6-difluorobenzoate,hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-amino-2,6-difluorobenzoate,hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-amino-2,6-difluorobenzoate,hydrochloride Use and application,methyl 3-amino-2,6-difluorobenzoate,hydrochloride technical grade,usp/ep/jp grade.

Related News: Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. Methyl 3-amino-2,6-difluorobenzoate hydrochloride manufacturer Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday. Methyl 3-amino-2,6-difluorobenzoate hydrochloride supplier During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. Methyl 3-amino-2,6-difluorobenzoate hydrochloride vendor Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday. Methyl 3-amino-2,6-difluorobenzoate hydrochloride factory During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology.